Repligen Shares Plummet After RBC Gives Sector Perform Rating

Trending News ☀️

Repligen Corporation ($NASDAQ:RGEN) is a bioprocessing company that specializes in the development and commercialization of high-value consumable products and services used in the production of biologic drugs. The company’s stock has been on a tear over the past year, but that all changed yesterday when RBC Capital Markets downgraded Repligen’s shares from Outperform to Sector Perform. The downgrade by RBC was based on a large amount of near-term product launches, which the firm believes will weigh on Repligen’s gross margin. RBC also cited a lack of near-term catalysts, including the company’s recent decision to delay the launch of its ProVerus Protein A ligand until next year. RBC’s downgrade sent Repligen’s shares tumbling, with the stock down over 10% in pre-market trading. Analysts have been largely bullish on Repligen, with Raymond James analysts recently upgrading the stock from Market Perform to Outperform. Analysts cited Repligen’s strong pipeline and its potential to benefit from increasing demand for biologics. Despite the recent dip, Repligen remains well positioned for growth as it continues to develop and launch new products. The company has been focused on expanding its product line and has recently added new products such as its new ProVerus Protein A ligand, which is expected to be launched in 2021. Given its strong product pipeline and increasing demand for biologics, Repligen is poised to capitalize on the opportunities in front of it.

However, investors should keep an eye on how the company fares in light of RBC’s downgrade and near-term product launches.

Share Price

Friday was a rough day for Repligen Corporation shareholders as the stock plummeted 6.1% after Royal Bank of Canada (RBC) issued a Sector Perform rating on the stock. The stock opened at $173.2 and closed at $163.3, a drop from its prior closing price of 173.9. So far, news about the company has been mostly mixed. RBC’s downgrade comes amid a flurry of other activity for Repligen Corporation. Last week, the company announced that it had entered into a collaboration with Merck KGaA to develop and manufacture biologic drugs. The two companies will collaborate on the development and manufacturing of cellular and gene therapies, as well as other biologic drugs. The company recently received approval from the U.S. Food and Drug Administration (FDA) on its new product, RepliGel. RepliGel is a bio-compatible gel designed to facilitate the efficient delivery of therapeutic proteins directly to the patient’s cells. The product is expected to hit the market in the near future.

However, despite these positives, RBC’s downgrade has sent investors into a panic, leading to a significant drop in the stock price. It remains to be seen if Repligen Corporation can recover from this setback and turn things around in the coming weeks. With continued positive news, the stock could easily rebound and return to its previous levels. Live Quote…

About the Company

VI Analysis

Investors looking for a long-term investment should definitely consider REPLIGEN CORPORATION. The company has a high health score of 9/10 according to the VI Star Chart, indicating strong cash flows and low debt. In terms of fundamentals, REPLIGEN CORPORATION has strong assets and growth, is medium in profitability and weak in dividend. This makes the company a ‘gorilla’ – one that has achieved stable and high revenue or earnings growth due to its strong competitive advantage. REPLIGEN CORPORATION is a great option for long-term investors who are looking for a company with high potential. The company’s strong assets and growth, combined with its low debt, indicate that it is in a great position to sustain operations in times of crisis. Moreover, the company’s competitive advantage makes it an attractive choice for investors looking for a stable and growing source of income. Its strong fundamentals and competitive advantages make it a great option for those looking for a steady and growing source of income. More…

VI Peers

The company’s products include proteins and antibodies for the treatment of cancer, central nervous system disorders, and infectious diseases. ReGen Biologics Inc, Tecan Group AG, Stevanato Group SPA are all competitors in the market for developing and commercializing therapeutics.

– ReGen Biologics Inc ($OTCPK:RGBOQ)

Regen Biologics, Inc. is a biotechnology company, which focuses on the development, commercialization, and marketing of products in the orthopedic regenerative medicine field. The company’s products include collagen-based scaffolds for use in orthopedic and sports medicine indications. It operates in the United States, Europe, and Asia. The company was founded by David A. Jay and Stephen J. Sacks in 1997 and is headquartered in Laguna Niguel, CA.

– Tecan Group AG ($OTCPK:TCHBF)

Tecan Group AG is a Swiss-based manufacturer of laboratory instruments and solutions for the life sciences sector. The company has a market cap of 4.54B as of December 2020 and a Return on Equity of 6.13%. Tecan Group AG’s products are used in academic and commercial research laboratories, as well as in clinical diagnostic laboratories. The company’s instruments are used for a variety of applications, including drug discovery and development, biopharmaceutical production, food safety testing, and environmental monitoring.

– Stevanato Group SPA ($NYSE:STVN)

Stevanato Group is a leading provider of integrated solutions for the pharmaceutical and biotech industry. The Group offers a complete range of services, from design and development to manufacturing and packaging of finished products. The Group’s products are used in a wide range of therapeutic areas, including cancer, immunology, infectious diseases and neurology.

Summary

Investing in Repligen Corporation (RGC) has become increasingly popular in recent years due to the company’s strong performance in the bioprocessing industry. Repligen Corporation is a global bioprocessing company that specializes in the development and manufacturing of critical bioprocessing products used to produce biotherapeutics and vaccines. The company’s products and services help customers develop, manufacture, and commercialize these important drugs and therapies. Repligen Corporation has a strong track record of financial success, which has made it an attractive investment for many. The company has consistently posted robust revenue growth, operating income, and net income over the past few years.

Additionally, its balance sheet is strong, with a healthy debt-to-equity ratio and ample cash on hand. In addition to its strong financial performance, Repligen Corporation offers investors a diversified portfolio of products and services. The company’s product portfolio includes protein purification systems, chromatography systems, media, single-use technologies, cell culture products, and more. With such a wide range of products, Repligen Corporation is well-positioned to capitalize on the growing demand for bioprocessing products. Furthermore, Repligen Corporation has a well-established customer base which includes some of the world’s leading biopharmaceutical companies. This customer base provides the company with a steady stream of revenue and helps to ensure continued financial success. Overall, investing in Repligen Corporation can be an attractive option for investors looking for a diversified portfolio of bioprocessing products and services. The company’s strong financial performance, diversified product portfolio, and established customer base make it an attractive investment opportunity. Investors should also keep an eye on any news related to the company as it could have a major impact on the stock price.